20.38 USD
▼-0.84-3.96%
盘后 24.51 0.00%
2026-09-15
市值
$3.21B
市盈率
—
EPS
-2.83
股息率
—
52 周区间
12.58 – 27.30
成交量
1.81M
Beta
1.01
目标价
36.06
52W 低 12.5852W 高 27.30
价格走势
公司简介
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzym...